Resistance mechanisms to epidermal growth factor receptor inhibitors in non-small cell lung cancer

Prabhash, Kumar; Bondili, SureshKumar; Nandhana, Ravindra; Noronha, Vanita; Joshi, Amit; Patil, Vijay; Menon, Nandini; Chougule, Anuradha; Shetty, Omshree; Kumar, Rajiv; Chandrani, Pratik; Mahajan, Abhishek; Chopade, Sunil

doi:10.4103/crst.crst_357_20

Cancer Res Stat Treat

2020

DOI: 10.4103/crst.crst_357_20

|View full text |Cite

Resistance mechanisms to epidermal growth factor receptor inhibitors in non-small cell lung cancer

Kumar Prabhash

SureshKumar Bondili

Ravindra Nandhana

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2021

2024

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 10 publications

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Real-World Experience of First-Line Osimertinib in EGFR Mutated Non-Small Cell Lung Cancers from a Tertiary Cancer Center, India

Tiwari,

Singh,

Noronha

et al. 2024

South Asian J Cancer

View full text Add to dashboard Cite

Osimertinib is approved in the first line in patients with mutations in the sensitive gene epidermal growth factor receptor (EGFR) mutation. There is lack of real-world evidence to illustrate the effectiveness and safety of osimertinib that can reflect the current medical practice especially in resource-constrained setting. A total of 129 patients with histology-proven metastatic non-small cell lung cancer with EGFR mutation registered at Tata Memorial Hospital between from March 2018 and May 2023 were analyzed. The parameters studied included demographics, outcomes, safety analysis, and secondary mutations. Most common EGFR mutation was exon 19 deletion 58.9% followed by EGFR exon 21 L858R 39.5% and others 1.5%. The overall median progression-free survival was 21.9 months (95% confidence interval [CI]: 16.0–58.1) and median overall survival was 31 months (95% CI: 17.8–45). The median duration of response was 21.3 months (95% CI: 17.1–25.5). Of 129 patients, 77.5% had partial response (PR), 10.1% had stable disease (SD), and 6.2% patients had progressive disease (PD) as the first best response with overall disease control rate was 87.2%. In patients with baseline central nervous system disease, 8.9% had complete response, 75.5% had PR and 8.9% had SD, and 2.2% had PD as best response. The overall intracranial response rate was 84.4% and disease control was 93.3%. Skin toxicities (27.1%) and gastrointestinal toxicities (17%) were most frequently observed toxicities. Overall, 63 patients had progression of disease on osimertinib. Subsequently, 58.7% (n = 37) patients received second line of therapy and 27% (n = 17) patients received third line of therapy. Platinum-based combination chemotherapy was the most common subsequent treatment after progression on osimertinib. Repeat biopsy was done in 33 patients (52.3%) and next-generation sequencing was done in 30 patients (47.6%). The most common resistance alteration detected was TP53 in 30% cases followed by mesenchymal epithelial transition (MET) amplification which was seen in 20% cases. Our study confirms similar efficacy and safety of osimertinib as first-line treatment of mutated non-small cell lung cancer in real-world setting irrespective of the type of common EGFR mutation and similar intracranial activity as well.

show abstract

Real-World Experience of First-Line Osimertinib in EGFR Mutated Non-Small Cell Lung Cancers from a Tertiary Cancer Center, India

Tiwari,

Singh,

Noronha

et al. 2024

South Asian J Cancer

View full text Add to dashboard Cite

show abstract

Lung cancer with dualEGFRandALKdriver alterations at baseline: a retrospective observational cohort study

et al. 2022

View full text Add to dashboard Cite

Met

Batra

Nathany

2022

Cancer Research, Statistics, and Treatment

View full text Add to dashboard Cite

The emergence of molecular medicine has led to the increased development and rapid approval of small molecule inhibitors which have caused a dramatic shift in the therapeutic landscape of non-small-cell lung cancer (NSCLC). Mesenchymal epithelial transition factor (MET) exon 14 skipping is one such alteration. This mutation has been reported in 3–4% of NSCLC cases. Additionally, MET exon 14 skipping mutation occurs in 2% of patients with squamous histology NSCLC, and hence, it should be tested in the first line setting. To prepare this review, we searched for articles using the keywords “MET,” “exon 14 skipping,” “capmatinib,” “tepotinib,” and “MET TKI” in databases such as PubMed, Scopus, and Embase. There were no defined inclusion/exclusion criteria for our search strategy as this was not a meta-analysis or a systematic review. This narrative review of MET covers its biology, with a special emphasis on exon 14 skipping mutation, its clinical features, and therapeutic options.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Resistance mechanisms to epidermal growth factor receptor inhibitors in non-small cell lung cancer

Cited by 10 publications

References 43 publications

Real-World Experience of First-Line Osimertinib in EGFR Mutated Non-Small Cell Lung Cancers from a Tertiary Cancer Center, India

Real-World Experience of First-Line Osimertinib in EGFR Mutated Non-Small Cell Lung Cancers from a Tertiary Cancer Center, India

Lung cancer with dualEGFRandALKdriver alterations at baseline: a retrospective observational cohort study

Met

Contact Info

Product

Resources

About